Two NIDDK programs, one focused on Type 1 Diabetes (see NIH grant RFA here) and one focused on Obesity (see NIH grant RFA here) funded three different groups with the goal of developing and disseminating targeted mass spectrometry assays for the diagnosis and monitoring of Type 1 Diabetes and Obesity. While the funding sources are separate, we felt there were obvious synergies in these efforts and formed TaMADOR with the goal of leveraging each other's capabilities and strengths.
Part of the project? Click HERE for internal resources (agendas, meeting logs, etc).
Quantifying Proteins in Plasma to Democratize Personalized Medicine for Patients with Type 1 Diabetes
Design and Validation of Easy-to-Adopt Mass Spectrometry Assays of Importance to Obesity
Multiplex Mass Spectrometric Protein Assays for Precise Monitoring of the Pathophysiology of Obesity
|UW and PNNL funded to develop assays for Type 1 diabetes||2023-09-06|
|Multiplexed quantification of insulin and C-peptide by LC-MS/MS without the use of antibodies||2023-09-06|
|2022 TaMADOR Meeting in Bethesda||2022-10-27|
|MSACL Workshop on the Development, Validation, and Implementation of Obesity and Diabetes Assays||2021-06-02|
|Announcing TaMADOR: A Collaborative Working Group for Targeted Mass Spectrometry Assays||2020-05-08|